Purpose: Intracellular calcium ([Ca 2+ ]i) overload is a major cause of cell injury during myocardial ischemia/reperfusion (I/R). Dexmedetomidine (DEX) has been shown to exert anti-inflammatory and organ protective effects. This study aimed to investigate whether pretreatment with DEX could protect H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation (OGD/R) injury through regulating the Ca 2+ signaling.
Introduction
Myocardial ischemia/reperfusion (I/R) injury is a major contributing factor of morbidity and mortality in patients with ischemic heart disease or after cardiac surgery. 1, 2 Studies identified various molecular and cellular mechanisms involved in the process of myocardial I/R. [3] [4] [5] [6] [7] Of these, intracellular calcium [Ca 2+ ]i overload is a critical one that leads to cardiomyocyte apoptosis and cell death. [8] [9] [10] Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist with sedative, anxiolytic, analgesic, and sympatholytic properties. 11, 12 Our previous studies showed that DEX use was associated with improved outcomes and reduced mortality in patients undergoing cardiac surgery. 13, 14 In a rat myocardial I/R model, DEX administration prior to ischemia (pretreatment) reduced the myocardial infarct size by inhibiting inflammation via the α2-adrenergic receptor activation. 15 DEX was also shown to inhibit muscarine-induced [Ca 2+ ]i elevation in the cultured dorsal root ganglion (DRG) cells via the muscarinic type 3 receptors. 16 However, whether DEX exerts cardiac protection through regulating the Ca 2+ signaling is unclear. The 12.6-kd FK506-binding protein (FKBP12.6, also known as calstabin-2), a member of the FKBPs family, regulates Ca 2+ release from cardiac sarcoplasmic reticulum (SR) via the interaction with cardiac ryanodine receptor 2 (RyR2). 17, 18 In pathological conditions, such as heart failure, binding of FKBP12.6 to RyR2 was evidently reduced. 4 Besides, He et al found a remarkably decreased ratio of FKBP12.6/RyR2 and an increased level of [Ca 2+ ]i in myocardial infarction rats. 19 Of note, RyR2 phosphorylation is a critical regulator of the channel function. 20 Phosphorylation of serine 2814 (Ser2814) on cardiac RyR2 was significantly increased in a time-dependent manner following reperfusion in wildtype mice, while knock-in mice with an inactivated RyR2 Ser2814 phosphorylation site had improved outcomes after reperfusion. 21, 22 Studies also revealed that the regulation of Ca 2+ in SR and cytoplasm was associated with the apoptotic signaling pathway. 12, 23, 24 In the apoptotic process, caspase-3 is known as an executioner that functions in DNA fragmentation and degradation of cytoskeletal proteins. 25 In this study, the effect of DEX pretreatment on Ca 2+ signaling and apoptosis in H9c2 cardiomyocytes during oxygen-glucose deprivation/reoxygenation (OGD/R) was investigated. We hypothesized that DEX could protect the cells against OGD/R-induced injury through alleviating [Ca 2+ ]i overload and inhibiting caspase-3 dependent apoptosis via the FKBP12.6/RyR2 signaling pathway.
Materials and methods

Cell culture
H9c2 cardiomyocytes, a rat embryonic heart-derived cell line (Shanghai Institute of Life Sciences, Chinese Academy of Sciences, Shanghai, China), were cultured in Dulbecco's modified Eagle's medium (DMEM, HyClone, USA) supplemented with 10% fetal bovine serum (FBS, Biological Industries, Israel), 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were grown in an incubator containing 5% CO 2 at 37°C for at least 24 h. Cells of 70-80% confluence were used for the experiments.
OGD/R model
H9c2 cardiomyocytes were treated with glucose-free DMEM and incubated at 37°C in a hypoxia chamber (95% N 2 and 5% CO 2 ), as previously described. 26 Cells were subjected to OGD for 12 h, and then cultured in the medium replaced by normal DMEM for 3 h of reoxygenation.
Experimental protocols
To determine the optimal concentration of DEX (Jiangsu Hengrui Medicine Co., Ltd, Jiangsu, China) against OGD/ R, cells were randomly divided into 5 groups: the control group (cells were cultured in DMEM with 10% FBS), the OGD/R group (cells underwent OGD/R), and 3 DEX groups (cells were treated with 0.1, 1, and 10 μM DEX for 1 h prior to OGD/R). The concentrations of DEX were based on our previous study. 27 To investigate the effects of FKBP12.6 knock-down by small interfering RNA (siRNA) (si-FKBP12.6; GenePharma, Shanghai, China) on H9c2 cardiomyocytes under OGD/R, cells were divided into 6 groups: the control group, the OGD/R group, the D1+OGD/R group (1 μM DEX prior to OGD/R), the si-FKBP12.6+D1+OGD/R group, the vehicle +D1+OGD/R group, and the mismatch+D1+OGD/R group. In the si-FKBP12.6+D1+OGD/R group, cells were transfected with FKBP12.6 siRNA using the RNAifectin TM (20 nM siRNA in 1 μL RNAifectin TM ; Applied Biological Materials, Richmond, BC, Canada) for 24 or 48 h before DEX treatment. In the vehicle+D1+OGD/R group, only 1 μL RNAifectinTM was applied. In the mismatch+D1+OGD/R group, cells were transfected with negative control sequences using RNAifectin TM . The siRNA oligo sequences are shown in Table 1 .
Cell viability assay
Cell viability was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M2128, Sigma Chemical Co. St. Louis, MO, USA) assay, as previously described. 28 Table 2 .
Western blots
Total protein was extracted and the protein concentration was determined using a bicinchoninic acid reagent kit (Beyotime, Shanghai, China), as previously described. 27 After electrophoresis on polyacrylamide gels (Bio-Rad, California, USA), proteins were transferred to polyvinylidene difluoride (PVDF) membranes at 200 mA at 4°C for 2 h. Then, the membranes were blocked for 2 h at room temperature, and incubated with the following primary antibodies at 4°C overnight: mouse anti-FKBP12.6 (1:1000, Santa Cruz Biotechnology, CA, USA), rabbit anti-RyR2 (1:1000, Signalway Antibody LLC, MD, USA), rabbit antipSer2814-RyR2 (1:5000, Badrilla, Leeds, Yorkshire, UK), rabbit anti-Caspase-3 (1:1000, Cell Signaling Technology, Beverly, MA, USA), and mouse anti-β-actin (1:1000, Cell Signaling Technology, Beverly, MA, USA). Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000, Santa Cruz Biotechnology, CA, USA) for 2 h at room temperature. Bands were visualized by a ChemiDoc TM XRS+ System (Bio-Rad, Richmond, CA) with an enhanced chemiluminescence kit (ECL, Beyotime, Shanghai, China). The protein expression was normalized to β-actin as a control.
Intracellular calcium analysis
Level of [Ca 2+ ]i was measured using the Fluo-3/AM staining (39294-1ML, Sigma, St. Louis, MO, USA) and Pluronic F127 (Sigma). To obtain the working solution, Pluronic F127 was added to Fluo-3/AM, which was diluted with Hanks' solution (Ca 2+ -free). The final concentration was 10 μM for Fluo-3/AM and 0.05% (w/v) for Pluronic F127. At the end of oxygenation, cells were incubated with working solution in dark environment at 
Hoechst staining
Cells were fixed with 4% formaldehyde for 10 min at room temperature, washed with phosphate-buffered saline (PBS) for three times, and incubated with 20 mmol/L Hoechst 33258 (Sigma) for 10 min at a dark room. The apoptotic cells with concentrated and fragmented bright blue nuclei were determined using a fluorescence microscopy (Olympus, Tokyo, Japan). Images were captured from random fields and data were presented as percentage of apoptotic cells to total cells.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism software (version 7.0, GraphPad, San Diego, CA, USA). Due to the small samples, the Shapiro-Wilk test was used for normality check. 29 Normally distributed data were expressed as mean ± standard error of the mean and compared using one-way or two-way analysis of variance followed by Bonferroni or Dunnet post-test as appropriate, whereas skewed data were expressed as median (interquartile range) and compared with non-parametric MannWhitney U test. A two-tailed value of P<0.05 indicates a statistically significant difference.
Results
DEX attenuated H9c2 cell injury induced by OGD/R
In the OGD/R group, H9c2 cells lost the normal shape. Specifically, cells became small and round, with decreased cell refraction. Pretreatment with 0.1, 1, and 10 μM DEX improved cell morphology ( Figure 1A ). MTT and LDH release assays were then used to measure the cell viability and cytotoxicity. OGD/R exposure significantly reduced cell viability (mean =52.9% of control, P<0.01) and (Figure 2A Figure 2C ).
DEX regulated FKBP12.6/RyR2 expression in H9c2 cells during OGD/R
To investigate whether FKBP12.6 and RyR2 were involved in the DEX-elicited protection against OGD/R in H9c2 cells, the mRNA and protein expression were measured. The RTqPCR and Western blot results showed significantly downregulated expression of FKBP12.6 after OGD/R, both in the mRNA and protein levels (mean fold change =0.51 and 0.59, P<0.01), which was reversed by pretreatment with 1 μM DEX (mean fold change =0.98 and 0.83, P<0.01) ( Figure 3A-C) . The expression of total RyR2 was not significantly altered by OGD/R or DEX ( Figure 3D-F) . OGD/R exposure significantly increased the expression of phosphorylated-Ser2814-RyR2 (p-S2814-RyR2) and the ratio of p-S2814-RyR2 to total RyR2 (P<0.01), which was blocked by DEX (P<0.05) ( Figure 3G and H). 
DEX reduced caspase-3 dependent apoptosis in H9c2 cells during OGD/R
The effect of DEX on cell apoptosis during OGD/R was investigated. The Hoechst staining results showed morphological changes typical of apoptosis (nuclear condensation and fragmentation) and elevated apoptosis rate (mean =54.0%, P<0.01) in OGD/R cells. The cell apoptosis was alleviated by pretreatment with 1 and 10 μM DEX (mean =28.3% and 28.6%, P<0.01), but not 0.1 μM DEX ( Figure 4A and B) . The protein expression of cleaved caspase-3 was up-regulated during OGD/R (P<0.01), while DEX reduced the expression of cleaved caspase-3 and the ratio of cleaved caspase-3 to caspase-3 (P<0.05) (Figure 4C-E) . The expression of caspase-3 remained unchanged during the process ( Figure 4F ).
Knockdown of FKBP12.6 abolished DEXelicited protection against OGD/Rinduced injury
To investigate the role of FKBP12.6 in the protective effects of DEX, cells were transfected with three different FKBP12.6 siRNAs (si-88, si-153, and si-240) for 24 and 48 h. The siRNAs significantly reduced FKBP12.6 mRNA levels compared to the control, vehicle, or mismatch groups, with better knockdown efficacy for 48 h (mean fold change =0.07 for si-88, 0.15 for si-153, and 0.12 for si-240, P<0.01) ( Figure 5A ). Next, Western blot results showed that si-88 was the most efficient one to inhibit the protein expression of FKBP12.6 (mean fold change =0.37, P<0.01) (Figure 5B and C) . Therefore, ]i levels (P<0.01) ( Figure 6A and B) . In addition, DEX pretreatment significantly inhibited the activation of p-S2814-RyR2 and reduced the ratio of p-S2814-RyR2 to total RyR2 (P<0.05), which was reversed by si-FKBP12.6 (P<0.01 for p-S2814-RyR2, P<0.05 for p-S2814-RyR2/RyR2) ( Figure 6C-E) . The protein expression of total RyR2 showed no significant change ( Figure 6F ).
Knockdown of FKBP12.6 abolished DEXelicited inhibition of cell apoptosis during OGD/R
Furthermore, whether pretreatment with DEX inhibited cell apoptosis via the FKBP12.6/RyR2 signaling pathway was determined. The Hoechst 33258 staining results showed that si-FKBP12.6 eliminated the inhibition of apoptosis by DEX in H9c2 cells (P<0.01) ( Figure 7A and B) . Next, the effect of si-FKBP12.6 on the caspase-3 signaling was also assessed. DEX significantly reduced the expression of cleaved caspase-3 during OGD/R and the ratio of cleaved caspase-3 to caspase-3 (P<0.05), and these effects were blocked by si-FKBP12.6 (P<0.05) (Figure 7C-E) . The expression of caspase-3 did not show significant change throughout the process ( Figure 7F ).
Discussion
Some possible mechanisms may underlie the DEX-induced protective effects against myocardial I/R injury, including inhibition of inflammation, activation of the eNOS/NO signaling, and maintaining a direct action. 15, 30, 31 It is also highlighted that disordered Ca 2+ homeostasis is a leading cause of ]i overload in rat hippocampal and DRG neurons during cerebral ischemia. 33 Another study reported that DEX modulated histamine-induced Ca 2+ signaling in cancer cell lines. 34 Based on our current findings, this is the first study to demonstrate that pretreatment with DEX protects H9c2 cardiomyocytes against OGD/R-induced injury by inhibiting [Ca 2+ ]i overload and caspase-3 dependent apoptosis through a direct regulation of the FKBP12.6/ RyR2 signaling (Figure 8) .
Studies showed that RyR2 dysfunction resulted in [Ca 2+ ]i overload during myocardial I/R injury. 35, 36 The suppression of RyR2-Ser2814 phosphorylation attenuated myocardial I/R injury by inhibiting cell apoptosis. 9 In our study, the increased RyR2-Ser2814 phosphorylation led to [Ca 2+ ]i overload in H9c2 cells exposed to OGD/R, which was inhibited by pretreatment with DEX. [Ca 2+ ]i overload eventually initiates the apoptotic process where caspase-3 protein acts as a critical executioner. 12, 24 A study found that DEX protected spinal cord against I/R-induced injury through inhibiting apoptosis and caspase-3 activation, 12 which was in line with the current results in H9c2 cells. As a regulatory protein, FKBP12.6 stabilizes the RyR channels, preventing Ca 2+ leakage from the SR. 37, 38 The decreased FKBP12.6 expression has been noted during rat myocardial I/R. 39 Our results showed that FKBP12.6 expression was down-regulated during OGD/R in H9c2 cells. Specifically, the disassociation of FKBP12.6 from RyR2 increased the spontaneous Ca 2+ spark frequency and Ca 2+ transient amplitude. 40, 41 FKBP12.6-deficient mice developed abnormal cardiac function, leading to exerciseinduced cardiac arrhythmia and sudden death. 42 On the other hand, FKBP12.6 over-expression improved cardiac function in mice after myocardial infarction. 43 Another study showed that FK506 induced disassociation of FKBP12.6 from RyR2, promoting SR stress-mediated apoptosis. 44 Our study suggests that the protective effect of DEX against OGD/R-induced injury in H9c2 cells was blocked by si-FKBP12.6, revealing the important role of FKBP12.6 in the OGD/R-induced [Ca 2+ ]i overload and DEX-mediated protection. In this regard, FKBP12.6 may be a promising therapeutic target for alleviating cardiac I/R injury. Our previous study indicated that DEX pretreatment alleviated myocardial I/R injury by inhibiting inflammation and down-regulating the expression of toll-like receptors 4 (TLR4)-myeloid differentiation primary response 88-nuclear factor-kappa B via the α2-adrenergic receptor. 15 A recent study showed that TLR4 activation induced Ca 2+ leakage via regulating FKBP12.6 dissociation from RyR2 in septic cardiomyocytes. TLR4-mediated FKBP12.6/RyR2 signaling pathway. In addition to the action on α2 adrenergic receptors, DEX may act on ion channels and membrane potential. 46 The diverse effects of DEX may be associated with its organ protective effects. 47 Using the whole cell patch clamp technique, one study showed that DEX attenuated L-type calcium channel and reduced Ca 2+ inward flow in rat ventricular myocytes. 48 Another study found that DEX inhibited Ca 2+ inward flow through voltage gated calcium channels and glutamate receptors in rat DRG and hippocampus. 33 Taken together, DEX may protect the cardiomyocytes through a direct effect on calciumrelated ion channels. The concentrations of DEX (0.1, 1, and 10 µM) in this study are higher than those clinically used for surgery and sedation. For humans, the maximum tolerated concentration of DEX is 15 ng/mL (equivalent to 75 nM). 49 For cultured cardiomyocytes, however, cell activity did not decrease when DEX concentrations <30 µM. 50 In our previous study, pretreatment with 1 µM DEX offered the best protection against hypoxia/reoxygenation-induced injury in H9c2 and primary neonatal rat cardiomyocytes. 27 In a recent study, 150 μM was the maximum safe concentration for DEX in PC12 cells, and 50 μM was eventually selected for the subsequent experiments. 51 Other studies used DEX 50 ng/mL (equivalent to 250 nM) on pacemaker cells in sinoatrial nodes of rabbits and DEX 200 ng/mL (equivalent to 1 µM) on rat ventricular myocytes. 48, 52 Therefore, it is possible that the safe concentration of DEX varies in different species and cell types. This study has several limitations. First, as the interaction of FKBP12.6 and RyR2 has been well identified, 18, 37, 38 the FKBP-RyR2 complex was not assessed by using a coimmunoprecipitation technique. Second, the present study focused on the regulation mechanism of DEX on the FKBP12.6/RyR2 signaling during OGD/R injury. However, Ca 2+ reuptake mediated by sarcoplasmic reticulum Ca
2+
-ATPase (SERCA) may have been another important mechanism underlying the effects of DEX, as many studies showed that SERCA played an important role on the regulation of Ca 2+ homeostasis in myocardial I/R injury. [53] [54] [55] Third, the current results in H9c2 cardiomyocytes may not be fully extrapolated to animal models or even humans. Last, whether DEX-induced protection against I/R-induced injury is associated with the above-mentioned ion channels needs to be clarified in our future studies.
In conclusion, this is the first study showing that pretreatment with DEX alleviated OGD/R-induced [Ca 2+ ]i overload and cell apoptosis in H9c2 cardiomyocytes through regulating the FKBP12.6/RyR2 signaling pathway. DEX may be used as a therapeutic agent for patients at high risk of myocardial I/R injury.
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